Robert Bradway, chairman and CEO said, “Robust growth in sales and earnings throughout 2024 reflects the momentum of our business. With strong performance globally, we are investing heavily in our rapidly advancing pipeline to deliver innovative therapies across our four therapeutic areas.”
Education
About Us
Working with TipRanks
Follow Us
1